Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialMary O’Brien, Solange Peters, Alex Martínez‐Martí et al.|The Lancet Oncology|2022Cited by 738
ESMO Guidance for Reporting Oncology real-World evidence (GROW)Luís Castelo-Branco, Miriam Koopman, Anna Pellat et al.|Annals of Oncology|2023Cited by 209
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee surveySusana Banerjee, Solange Peters, Urania Dafni et al.|ESMO Open|2018Cited by 77
Report on the status of women occupying leadership roles in oncologyEva Hofstädter-Thalmann, Solange Peters, Urania Dafni et al.|ESMO Open|2018Cited by 49